home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

8.770 +0.030 (+0.34%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Insiders Selling Meta Platforms And 3 Other Stocks ↗

February 10, 2023

The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

The 7 Most Undervalued Biotech Stocks to Buy in February 2023 ↗

February 02, 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

Via InvestorPlace

7 Healthcare Stocks That Will Be Big Winners in 2023 ↗

January 31, 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

Via InvestorPlace

5 Value Stocks In The Healthcare Sector ↗

January 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗

January 27, 2023

Via Benzinga

Analyst Expectations for Vir Biotechnology's Future ↗

January 27, 2023

Via Benzinga

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

January 25, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

2 Stocks That Could Turn $100 Into $1,000 by 2028 ↗

January 22, 2023

These growth stocks have substantial tailwinds.

Via The Motley Fool

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

December 21, 2022

– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –

From Vir Biotechnology, Inc.

Via GlobeNewswire

2 Fast-Growing Healthcare Stocks to Buy and Hold ↗

December 02, 2022

The innovative companies have made great gains in a short period of time.

Via The Motley Fool

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗

December 02, 2022

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...

Via Benzinga

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗

November 18, 2022

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

Via Benzinga

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

November 16, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action ↗

November 07, 2022

Via Benzinga

Why Vir Biotechnology Jumped Nearly 19% Today ↗

November 04, 2022

A COVID-19 partnership with a major drugmaker is producing more fruit than expected.

Via The Motley Fool

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting ↗

November 15, 2022

Via Benzinga

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection

November 06, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 04, 2022

Gainers

Via Benzinga

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session ↗

November 04, 2022

Gainers

Via Benzinga

What 5 Analyst Ratings Have To Say About Vir Biotechnology ↗

November 04, 2022

Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth ↗

November 04, 2022

Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates.

Via Investor's Business Daily

Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday ↗

November 04, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 03, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022

October 31, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

October 28, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com